RU2733985C2 - Пептиды neil3 и включающие их вакцины - Google Patents

Пептиды neil3 и включающие их вакцины Download PDF

Info

Publication number
RU2733985C2
RU2733985C2 RU2016138428A RU2016138428A RU2733985C2 RU 2733985 C2 RU2733985 C2 RU 2733985C2 RU 2016138428 A RU2016138428 A RU 2016138428A RU 2016138428 A RU2016138428 A RU 2016138428A RU 2733985 C2 RU2733985 C2 RU 2733985C2
Authority
RU
Russia
Prior art keywords
neil3
peptide
peptides
cancer
present
Prior art date
Application number
RU2016138428A
Other languages
English (en)
Russian (ru)
Other versions
RU2016138428A3 (enExample
RU2016138428A (ru
Inventor
Такуя Цунода
Рюдзи ОХСАВА
Сатико Йосимура
Томохиса Ватанабе
Юсуке Накамура
Йоити ФУРУКАВА
Original Assignee
Онкотерапи Сайенс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапи Сайенс, Инк. filed Critical Онкотерапи Сайенс, Инк.
Publication of RU2016138428A publication Critical patent/RU2016138428A/ru
Publication of RU2016138428A3 publication Critical patent/RU2016138428A3/ru
Application granted granted Critical
Publication of RU2733985C2 publication Critical patent/RU2733985C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/99—Other carbon-oxygen lyases (4.2.99)
    • C12Y402/99018—DNA-(apurinic or apyrimidinic site)lyase (4.2.99.18)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
RU2016138428A 2009-03-18 2010-03-15 Пептиды neil3 и включающие их вакцины RU2733985C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21051209P 2009-03-18 2009-03-18
US61/210,512 2009-03-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2011142036/10A Division RU2600888C2 (ru) 2009-03-18 2010-03-15 Пептиды neil3 и включающие их вакцины

Publications (3)

Publication Number Publication Date
RU2016138428A RU2016138428A (ru) 2018-12-12
RU2016138428A3 RU2016138428A3 (enExample) 2020-03-27
RU2733985C2 true RU2733985C2 (ru) 2020-10-09

Family

ID=42739437

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016138428A RU2733985C2 (ru) 2009-03-18 2010-03-15 Пептиды neil3 и включающие их вакцины
RU2011142036/10A RU2600888C2 (ru) 2009-03-18 2010-03-15 Пептиды neil3 и включающие их вакцины

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2011142036/10A RU2600888C2 (ru) 2009-03-18 2010-03-15 Пептиды neil3 и включающие их вакцины

Country Status (20)

Country Link
US (4) US9045557B2 (enExample)
EP (1) EP2408913B1 (enExample)
JP (3) JP5799394B2 (enExample)
KR (1) KR101744514B1 (enExample)
CN (2) CN102356155B (enExample)
BR (1) BRPI1009301A2 (enExample)
CA (1) CA2755342C (enExample)
DK (1) DK2408913T3 (enExample)
ES (1) ES2617434T3 (enExample)
HU (1) HUE030856T2 (enExample)
IL (2) IL214130A (enExample)
MX (1) MX2011007963A (enExample)
NZ (1) NZ594198A (enExample)
PL (1) PL2408913T3 (enExample)
PT (1) PT2408913T (enExample)
RU (2) RU2733985C2 (enExample)
SG (2) SG174120A1 (enExample)
TW (2) TWI608844B (enExample)
WO (1) WO2010106770A1 (enExample)
ZA (1) ZA201107356B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
US8933014B2 (en) 2010-03-11 2015-01-13 Oncotherapy Science, Inc. HJURP peptides and vaccines including the same
TWI618541B (zh) * 2010-12-02 2018-03-21 腫瘤療法 科學股份有限公司 Ｔｏｍｍ３４胜肽與含此胜肽之疫苗
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
JP6078844B2 (ja) * 2012-09-26 2017-02-15 公立大学法人大阪市立大学 癌免疫療法のためのペプチド及びその利用
US20170224799A1 (en) * 2014-09-10 2017-08-10 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
JP6426486B2 (ja) * 2015-01-29 2018-11-21 京セラ株式会社 太陽電池素子の製造方法
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048646A1 (en) * 2003-08-25 2005-03-03 Medinet Co., Ltd. Method for inducing cytotoxic T lymphocyte

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU749544B2 (en) 1998-06-25 2002-06-27 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen peptides originating in cyclophilin B
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2384713A1 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1325120A4 (en) * 2000-10-12 2005-05-25 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
EP2336167B1 (en) 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
WO2003104275A2 (en) 2002-06-06 2003-12-18 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
EP2267023B1 (en) * 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
DK1987178T3 (en) * 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
WO2008156827A2 (en) * 2007-06-20 2008-12-24 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular grading methods for ductal carcinoma in situ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048646A1 (en) * 2003-08-25 2005-03-03 Medinet Co., Ltd. Method for inducing cytotoxic T lymphocyte

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAN J.F. et al."Identification of a new HLA-A* 0201-restricted cytotoxic T lymphocyte epitope fromCML28." Cancer Immunology, Immunotherapy (2006); 55: 1575-1583. *
KONDO A. et al. "Prominentroles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules."The Journal of Immunology (1995); 155(9): 4307-4312 *
TORISU K. et al. "Hematopoietic Tissue-Specific Expression of Mouse Neil3 for Endonuclease VIII-Like Protein." Journal of biochemistry (2005); 138(6): 763-772. *
TORISU K. et al. "Hematopoietic Tissue-Specific Expression of Mouse Neil3 for Endonuclease VIII-Like Protein." Journal of biochemistry (2005); 138(6): 763-772. HAN J.F. et al. "Identification of a new HLA-A* 0201-restricted cytotoxic T lymphocyte epitope from CML28." Cancer Immunology, Immunotherapy (2006); 55: 1575-1583. KONDO A. et al. "Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules." The Journal of Immunology (1995); 155(9): 4307-4312. *
БАЛДУЕВА И.А., "Противоопухолевые Вакцины", Практическая Онкология (2003), 4(3):157-166. *

Also Published As

Publication number Publication date
TW201600107A (zh) 2016-01-01
US9045557B2 (en) 2015-06-02
RU2016138428A3 (enExample) 2020-03-27
BRPI1009301A2 (pt) 2016-03-08
IL214130A0 (en) 2011-08-31
MX2011007963A (es) 2011-08-17
US20150290307A1 (en) 2015-10-15
RU2016138428A (ru) 2018-12-12
PL2408913T3 (pl) 2017-07-31
RU2011142036A (ru) 2013-04-27
CN105601725B (zh) 2019-08-09
WO2010106770A1 (en) 2010-09-23
SG174120A1 (en) 2011-10-28
ZA201107356B (en) 2012-07-25
NZ594198A (en) 2013-11-29
TW201043240A (en) 2010-12-16
EP2408913A1 (en) 2012-01-25
KR20110139270A (ko) 2011-12-28
JP2017132786A (ja) 2017-08-03
PT2408913T (pt) 2017-03-07
CA2755342A1 (en) 2010-09-23
EP2408913B1 (en) 2016-12-14
HUE030856T2 (en) 2017-06-28
CA2755342C (en) 2017-10-03
JP5799394B2 (ja) 2015-10-28
KR101744514B1 (ko) 2017-06-08
US9975935B2 (en) 2018-05-22
CN105601725A (zh) 2016-05-25
TWI608844B (zh) 2017-12-21
DK2408913T3 (en) 2017-03-06
JP2015227334A (ja) 2015-12-17
IL229926A (en) 2016-11-30
JP2012520659A (ja) 2012-09-10
CN102356155B (zh) 2016-02-24
SG2014013148A (en) 2014-07-30
EP2408913A4 (en) 2012-11-14
US9446106B2 (en) 2016-09-20
US20160340398A1 (en) 2016-11-24
US10597431B2 (en) 2020-03-24
ES2617434T3 (es) 2017-06-19
IL214130A (en) 2017-09-28
US20180222954A1 (en) 2018-08-09
RU2600888C2 (ru) 2016-10-27
US20120093845A1 (en) 2012-04-19
AU2010225997A1 (en) 2011-08-11
CN102356155A (zh) 2012-02-15
TWI568444B (zh) 2017-02-01
IL229926A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
US10597431B2 (en) NEIL3 peptides and vaccines including the same
JP2016222676A (ja) Ｔｏｍｍ３４ペプチドおよびそれを含むワクチン
WO2010100878A1 (en) Vangl1 peptides and vaccines including the same
JP5838482B2 (ja) Ｈｊｕｒｐペプチドおよびそれを含むワクチン
WO2012032764A1 (en) Ttll4 peptides and vaccines containing the same
CA2782977A1 (en) Tmem22 peptides and vaccines including the same
JP2014504146A (ja) Ｗｄｈｄ１ペプチドおよびそれを含むワクチン
JP2014500001A (ja) Ｃ１８ｏｒｆ５４ペプチドおよびそれを含むワクチン
AU2010225997B2 (en) NEIL3 peptides and vaccines including the same
HK1166097B (en) Neil3 peptides and vaccines including the same
HK1166097A (en) Neil3 peptides and vaccines including the same